One Week of Oral Camostat Versus Placebo in Non-Hospitalized Adults with Mild-to-Moderate COVID-19: A Randomized Controlled Phase 2 Trial

By sjmartinez • June 7, 2023

Jilg N, Chew KW, Giganti MJ, Daar ES, Wohl DA, Javan AC, Kantor A, Moser C, Coombs RW, Neytman G, Hoover K, Jana A, Hart PA, Greninger AL, Szurgot B, Eron JJ, Currier JS, Hughes MD, Smith DM, Li JZ; ACTIV-2/A5401 Study Team. One Week of Oral Camostat Versus Placebo in Non-Hospitalized Adults with Mild-to-Moderate COVID-19: A Randomized Controlled Phase 2 Trial. Clin Infect Dis. 2023 Jun 5:ciad342. doi: 10.1093/cid/ciad342. Epub ahead of print. PMID: 37279602.

Tags: camostat, covid-19, Infectious Diseases, outpatient, phase 2, Publications, SARS-CoV-2

HIV Drug Resistance to Dolutegravir Among Adults Investigated for Anti-retroviral Treatment Failure in Malawi: A 2023 National Cross-sectional Survey

Kalata NL, Bello G, Pals S, Kabaghe AN, Mkungudza J, Bighignoli B, Panja L, Bilaal W, Kusakale G, Chitenje M, Luhanga M, Zeh C, Kampira[...]

Frailty, Pitavastatin, and Major Adverse Cardiovascular Events Among People With HIV

Erlandson KM, Orkaby AR, Umbleja T, Ribaudo HJ, Brown TT, Zanni MV, Diggs MR, Chu SM, Fitch KV, Fichtenbaum CJ, Malvestutto C, Aberg JA, Bloomfield[...]

Late BK Nephropathy 15 years post kidney transplant following chemotherapy: A case report

Hamiduzzaman A, Hou J, Higgins T, Gaynor P, Shankar A, Lum EL. Late BK Nephropathy 15 years post kidney transplant following chemotherapy: A case report.[...]